|
MX2009010611A
(es)
*
|
2007-04-03 |
2010-03-26 |
Micromet Ag |
Enlazadores biespecificos, especificos para especies.
|
|
US12492253B1
(en)
*
|
2008-02-25 |
2025-12-09 |
Xencor, Inc. |
Anti-human C5 antibodies
|
|
PT3434767T
(pt)
|
2010-11-30 |
2026-01-23 |
Chugai Pharmaceutical Co Ltd |
Agente terapêutico indutor de citotoxicidade
|
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對ｂｃｍａ之e3以及ｃｄ３的結合分子
|
|
JP6313712B2
(ja)
*
|
2011-12-21 |
2018-04-18 |
アムジエン・インコーポレーテツド |
新生児Ｆｃ受容体への結合を強化された変異型Ｆｃポリペプチド
|
|
AU2013289883B2
(en)
*
|
2012-07-13 |
2018-11-01 |
Zymeworks Bc Inc. |
Bispecific asymmetric heterodimers comprising anti-CD3 constructs
|
|
US20140302037A1
(en)
*
|
2013-03-15 |
2014-10-09 |
Amgen Inc. |
BISPECIFIC-Fc MOLECULES
|
|
US11634502B2
(en)
*
|
2013-03-15 |
2023-04-25 |
Amgen Inc. |
Heterodimeric bispecific antibodies
|
|
CN105377897A
(zh)
|
2013-05-03 |
2016-03-02 |
俄亥俄州创新基金会 |
Cs1-特异性嵌合抗原受体工程化的免疫效应细胞
|
|
AU2014357292B2
(en)
|
2013-11-27 |
2020-06-25 |
Zymeworks Bc Inc. |
Bispecific antigen-binding constructs targeting HER2
|
|
IL263466B2
(en)
|
2013-12-17 |
2023-10-01 |
Genentech Inc |
Anti-CD3 antibodies and methods of using them
|
|
AU2015244814B2
(en)
|
2014-04-07 |
2020-12-24 |
Chugai Seiyaku Kabushiki Kaisha |
Immunoactivating antigen-binding molecule
|
|
MX2016014434A
(es)
*
|
2014-05-13 |
2017-02-23 |
Chugai Pharmaceutical Co Ltd |
Molecula de union a antigeno redirigida a celulas t para celulas que tienen funcion de inmunosupresion.
|
|
GB201411320D0
(en)
|
2014-06-25 |
2014-08-06 |
Ucb Biopharma Sprl |
Antibody construct
|
|
CA2955947A1
(en)
|
2014-07-25 |
2016-01-28 |
Cytomx Therapeutics, Inc. |
Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
|
|
EP3174901B1
(en)
|
2014-07-31 |
2019-06-26 |
Amgen Research (Munich) GmbH |
Optimized cross-species specific bispecific single chain antibody constructs
|
|
MX2017003847A
(es)
*
|
2014-09-25 |
2017-12-15 |
Amgen Inc |
Proteinas biespecificas activables por proteasas.
|
|
US11566082B2
(en)
|
2014-11-17 |
2023-01-31 |
Cytiva Bioprocess R&D Ab |
Mutated immunoglobulin-binding polypeptides
|
|
DK3221357T3
(da)
|
2014-11-20 |
2020-08-10 |
Hoffmann La Roche |
Fælles letkæder og fremgangsmåder til anvendelse
|
|
PT3221356T
(pt)
|
2014-11-20 |
2020-10-29 |
Hoffmann La Roche |
Moléculas de ligação ao antigénio biespecíficas ativadoras das células t contra folr1 e cd3
|
|
EP4141032B1
(en)
|
2014-11-20 |
2024-05-29 |
F. Hoffmann-La Roche AG |
Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists
|
|
WO2016134371A2
(en)
*
|
2015-02-20 |
2016-08-25 |
Ohio State Innovation Foundation |
Bivalent antibody directed against nkg2d and tumor associated antigens
|
|
US11045543B2
(en)
|
2015-04-06 |
2021-06-29 |
Cytoimmune Therapeutics, Inc. |
EGFR-directed car therapy for glioblastoma
|
|
CN107750255B
(zh)
|
2015-04-17 |
2022-08-30 |
安进研发（慕尼黑）股份有限公司 |
用于cdh3和cd3的双特异性抗体构建体
|
|
EP3288981A1
(en)
*
|
2015-05-01 |
2018-03-07 |
Genentech, Inc. |
Masked anti-cd3 antibodies and methods of use
|
|
EP3296395B2
(en)
|
2015-05-13 |
2024-06-19 |
Chugai Seiyaku Kabushiki Kaisha |
Multiple antigen binding molecular fusion, pharmaceutical composition, method for identifying linear epitope, and method for preparing multiple antigen binding molecular fusion
|
|
US9708412B2
(en)
|
2015-05-21 |
2017-07-18 |
Harpoon Therapeutics, Inc. |
Trispecific binding proteins and methods of use
|
|
WO2017011414A1
(en)
*
|
2015-07-10 |
2017-01-19 |
Duke University |
Bispecific molecules comprising an hiv-1 envelope targeting arm
|
|
WO2017011413A1
(en)
*
|
2015-07-10 |
2017-01-19 |
Duke University |
Bispecific molecules comprising an hiv-1 envelope targeting arm
|
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究（慕尼黑）公司 |
Ｆｌｔ３及ｃｄ３抗體構築體
|
|
EA039859B1
(ru)
|
2015-07-31 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究（慕尼黑）公司 |
Ｍｓｌｎ及ｃｄ３抗體構築體
|
|
TWI793062B
(zh)
|
2015-07-31 |
2023-02-21 |
德商安美基研究（慕尼黑）公司 |
Ｄｌｌ３及ｃｄ３抗體構築體
|
|
TWI717375B
(zh)
|
2015-07-31 |
2021-02-01 |
德商安美基研究（慕尼黑）公司 |
Ｃｄ７０及ｃｄ３抗體構築體
|
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究（慕尼黑）公司 |
Egfrviii及cd3抗體構築體
|
|
JO3620B1
(ar)
|
2015-08-05 |
2020-08-27 |
Amgen Res Munich Gmbh |
مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
|
|
US20190002563A1
(en)
*
|
2015-08-17 |
2019-01-03 |
Macrogenics, Inc. |
Bispecific Monovalent Diabodies That are Capable of Binding B7-H3 and CD3, and Uses Thereof
|
|
PE20180484A1
(es)
*
|
2015-10-02 |
2018-03-07 |
Hoffmann La Roche |
Moleculas biespecificas de union a antigeno activadoras de celulas t
|
|
JP2018533930A
(ja)
*
|
2015-10-02 |
2018-11-22 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
二重特異性ｔ細胞活性化抗原結合分子
|
|
RS62437B1
(sr)
|
2015-10-25 |
2021-11-30 |
Sanofi Sa |
Trispecifični i/ili trivalentni vezujući proteini za prevenciju ili lečenje hiv infekcije
|
|
CN107207608B
(zh)
*
|
2015-10-30 |
2021-05-11 |
江苏众红生物工程创药研究院有限公司 |
双特异性抗体、其制备方法和用途
|
|
WO2017086367A1
(ja)
|
2015-11-18 |
2017-05-26 |
中外製薬株式会社 |
免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
|
|
WO2017086419A1
(ja)
|
2015-11-18 |
2017-05-26 |
中外製薬株式会社 |
液性免疫応答の増強方法
|
|
IL313608A
(en)
|
2015-12-09 |
2024-08-01 |
Hoffmann La Roche |
Antibody against CD20 type II to reduce the formation of antibodies against drugs
|
|
KR20180097615A
(ko)
|
2016-01-08 |
2018-08-31 |
에프. 호프만-라 로슈 아게 |
Pd-1 축 결합 길항물질 및 항-cea/항-cd3 이중특이성 항체를 사용하는 cea-양성 암의 치료 방법
|
|
IL313507A
(en)
|
2016-02-03 |
2024-08-01 |
Amgen Res Munich Gmbh |
Constructs of bispecific antibodies to BCMA and CD3 that bind to T cells, preparations containing the same and uses thereof
|
|
EA201891753A1
(ru)
|
2016-02-03 |
2019-01-31 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкции антител к psma и cd3, вовлекающие т-клетки
|
|
WO2017165464A1
(en)
|
2016-03-21 |
2017-09-28 |
Elstar Therapeutics, Inc. |
Multispecific and multifunctional molecules and uses thereof
|
|
WO2017162587A1
(en)
*
|
2016-03-22 |
2017-09-28 |
F. Hoffmann-La Roche Ag |
Protease-activated t cell bispecific molecules
|
|
JP7015244B2
(ja)
|
2016-03-22 |
2022-02-02 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
プロテアーゼ活性化ｔ細胞二重特異性分子
|
|
CA3020633A1
(en)
|
2016-04-13 |
2017-10-19 |
Sanofi |
Trispecific and/or trivalent binding proteins
|
|
LT3443006T
(lt)
|
2016-04-13 |
2023-10-25 |
Sanofi |
Trispecifiniai ir (arba) trivalenčiai rišantieji baltymai
|
|
JOP20170091B1
(ar)
|
2016-04-19 |
2021-08-17 |
Amgen Res Munich Gmbh |
إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
|
|
US10889615B2
(en)
|
2016-05-11 |
2021-01-12 |
Cytiva Bioprocess R&D Ab |
Mutated immunoglobulin-binding polypeptides
|
|
WO2017194593A1
(en)
|
2016-05-11 |
2017-11-16 |
Ge Healthcare Bioprocess R&D Ab |
Method of cleaning and/or sanitizing a separation matrix
|
|
US10703774B2
(en)
|
2016-09-30 |
2020-07-07 |
Ge Healthcare Bioprocess R&D Ab |
Separation method
|
|
US10730908B2
(en)
|
2016-05-11 |
2020-08-04 |
Ge Healthcare Bioprocess R&D Ab |
Separation method
|
|
JP7031934B2
(ja)
|
2016-05-11 |
2022-03-08 |
サイティバ・バイオプロセス・アールアンドディ・アクチボラグ |
分離マトリックス
|
|
US10654887B2
(en)
|
2016-05-11 |
2020-05-19 |
Ge Healthcare Bio-Process R&D Ab |
Separation matrix
|
|
US10513537B2
(en)
|
2016-05-11 |
2019-12-24 |
Ge Healthcare Bioprocess R&D Ab |
Separation matrix
|
|
WO2017194592A1
(en)
|
2016-05-11 |
2017-11-16 |
Ge Healthcare Bioprocess R&D Ab |
Method of storing a separation matrix
|
|
WO2017201493A1
(en)
|
2016-05-20 |
2017-11-23 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment cd3 binding proteins
|
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
|
EP3493844A4
(en)
|
2016-05-20 |
2021-03-24 |
Harpoon Therapeutics Inc. |
SINGLE DOMAIN SERUM ALBUMIN BINDING PROTEIN
|
|
DK3484514T3
(da)
*
|
2016-05-23 |
2024-01-29 |
Momenta Pharmaceuticals Inc |
Compositions and methods related to engineered fc constructs
|
|
WO2018014001A1
(en)
|
2016-07-14 |
2018-01-18 |
Fred Hutchinson Cancer Research Center |
Multiple bi-specific binding domain constructs with different epitope binding to treat cancer
|
|
KR102579850B1
(ko)
|
2016-07-22 |
2023-09-18 |
암젠 인크 |
Fc-함유 단백질의 정제 방법
|
|
US10696722B2
(en)
|
2016-08-10 |
2020-06-30 |
Ajou University Industry-Academic Cooperation Foundation |
Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same
|
|
US12448411B2
(en)
|
2016-09-30 |
2025-10-21 |
Cytiva Bioprocess R&D Ab |
Separation method
|
|
JP7784795B2
(ja)
|
2016-11-15 |
2025-12-12 |
ジェネンテック， インコーポレイテッド |
抗ｃｄ２０／抗ｃｄ３二重特異性抗体による処置のための投与
|
|
AU2017363300A1
(en)
|
2016-11-23 |
2019-06-20 |
Harpoon Therapeutics, Inc. |
Prostate specific membrane antigen binding protein
|
|
WO2018098356A1
(en)
|
2016-11-23 |
2018-05-31 |
Harpoon Therapeutics, Inc. |
Psma targeting trispecific proteins and methods of use
|
|
SMT202500367T1
(it)
|
2017-02-02 |
2025-11-10 |
Amgen Res Munich Gmbh |
Composizione farmaceutica a basso ph comprendente costrutti di anticorpo che reclutano le cellule t
|
|
WO2018151820A1
(en)
|
2017-02-16 |
2018-08-23 |
Elstar Therapeutics, Inc. |
Multifunctional molecules comprising a trimeric ligand and uses thereof
|
|
US11535668B2
(en)
|
2017-02-28 |
2022-12-27 |
Harpoon Therapeutics, Inc. |
Inducible monovalent antigen binding protein
|
|
UY37726A
(es)
|
2017-05-05 |
2018-11-30 |
Amgen Inc |
Composición farmacéutica que comprende constructos de anticuerpos biespecíficos para almacenamiento y administración mejorados
|
|
WO2018209304A1
(en)
|
2017-05-12 |
2018-11-15 |
Harpoon Therapeutics, Inc. |
Msln targeting trispecific proteins and methods of use
|
|
EP3621994A4
(en)
|
2017-05-12 |
2020-12-30 |
Harpoon Therapeutics, Inc. |
MESOTHELIN BINDING PROTEINS
|
|
EP3630836A1
(en)
|
2017-05-31 |
2020-04-08 |
Elstar Therapeutics, Inc. |
Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
|
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
|
MX2020003915A
(es)
|
2017-10-13 |
2020-10-08 |
Harpoon Therapeutics Inc |
Proteinas trispecificas y metodos de uso.
|
|
IL315737A
(en)
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
|
EP3694885A1
(en)
|
2017-10-14 |
2020-08-19 |
CytomX Therapeutics, Inc. |
Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
|
|
EP3703731A4
(en)
|
2017-11-04 |
2021-07-21 |
Aravive Biologics, Inc. |
METHOD OF TREATMENT OF METASTATIC CANCER USING AXL DECOY RECEPTORS
|
|
AU2018383679B2
(en)
|
2017-12-11 |
2025-10-09 |
Amgen Inc. |
Continuous manufacturing process for bispecific antibody products
|
|
AU2018387829B2
(en)
|
2017-12-22 |
2024-12-19 |
Argenx Bvba |
Bispecific antigen binding construct
|
|
TW201940518A
(zh)
|
2017-12-29 |
2019-10-16 |
美商安進公司 |
針對ｍｕｃ１７和ｃｄ３之雙特異性抗體構建體
|
|
US12247060B2
(en)
|
2018-01-09 |
2025-03-11 |
Marengo Therapeutics, Inc. |
Calreticulin binding constructs and engineered T cells for the treatment of diseases
|
|
IL325995A
(en)
|
2018-02-08 |
2026-03-01 |
Genentech Inc |
Bispecific antigen binding molecules and methods of use
|
|
GB201802487D0
(en)
|
2018-02-15 |
2018-04-04 |
Argenx Bvba |
Cytokine combination therapy
|
|
AU2019236091B2
(en)
|
2018-03-13 |
2025-06-05 |
Phanes Therapeutics, Inc. |
Anti-folate receptor 1 antibodies and uses thereof
|
|
EP3765516A2
(en)
|
2018-03-14 |
2021-01-20 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
|
EP3765517A1
(en)
|
2018-03-14 |
2021-01-20 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
US11168138B2
(en)
|
2018-03-26 |
2021-11-09 |
Altor Bioscience, Llc |
Anti-PDL1, IL-15 and TGF-beta receptor combination molecules
|
|
BR112020023330A2
(pt)
|
2018-05-14 |
2021-04-20 |
Harpoon Therapeutics, Inc. |
porção de ligação para ativação condicional de moléculas de imunoglobulina
|
|
CA3105448A1
(en)
|
2018-07-03 |
2020-01-09 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
CA3107186A1
(en)
*
|
2018-07-30 |
2020-02-06 |
Amgen Research (Munich) Gmbh |
Prolonged administration of a bispecific antibody construct binding to cd33 and cd3
|
|
CA3105729A1
(en)
|
2018-07-31 |
2020-02-06 |
Amgen Research (Munich) Gmbh |
Dosing regimen for bcma-cd3 bispecific antibodies
|
|
WO2020025792A1
(en)
|
2018-08-03 |
2020-02-06 |
Amgen Research (Munich) Gmbh |
Antibody constructs for cldn18.2 and cd3
|
|
US12195544B2
(en)
|
2018-09-21 |
2025-01-14 |
Harpoon Therapeutics, Inc. |
EGFR binding proteins and methods of use
|
|
US10815311B2
(en)
|
2018-09-25 |
2020-10-27 |
Harpoon Therapeutics, Inc. |
DLL3 binding proteins and methods of use
|
|
US20220002370A1
(en)
|
2018-09-27 |
2022-01-06 |
Xilio Development, Inc. |
Masked cytokine polypeptides
|
|
MA53732A
(fr)
|
2018-09-28 |
2022-01-05 |
Amgen Inc |
Anticorps dirigés contre bcma soluble
|
|
JP7644706B2
(ja)
|
2018-10-11 |
2025-03-12 |
アムジエン・インコーポレーテツド |
二重特異性抗体コンストラクトの下流プロセシング
|
|
MX2021004510A
(es)
|
2018-10-23 |
2021-06-08 |
Amgen Inc |
Calibracion automatica y mantenimiento automatico de modelos espectroscopicos de raman para predicciones en tiempo real.
|
|
SG11202104136YA
(en)
*
|
2018-10-23 |
2021-05-28 |
Dragonfly Therapeutics Inc |
Heterodimeric fc-fused proteins
|
|
JP7410143B2
(ja)
*
|
2018-11-01 |
2024-01-09 |
山▲東▼新▲時▼代▲薬▼▲業▼有限公司 |
二重特異性抗体及びその用途
|
|
MX2021006389A
(es)
|
2018-12-07 |
2021-07-15 |
Jiangsu Hengrui Medicine Co |
Anticuerpo cd3 y uso farmaceutico del mismo.
|
|
AU2019412561A1
(en)
|
2018-12-24 |
2021-08-12 |
Sanofi |
Multispecific binding proteins with mutant Fab domains
|
|
TWI871300B
(zh)
|
2019-01-28 |
2025-02-01 |
美商安進公司 |
藉由將藥物物質和藥物產品過程整體化的生物製劑製造之連續製造過程
|
|
GB2599228B
(en)
|
2019-02-21 |
2024-02-07 |
Marengo Therapeutics Inc |
Multifunctional molecules that bind to T cell related cancer cells and uses thereof
|
|
CN119039441A
(zh)
|
2019-02-21 |
2024-11-29 |
马伦戈治疗公司 |
与nkp30结合的抗体分子及其用途
|
|
EP3927746A1
(en)
|
2019-02-21 |
2021-12-29 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
EP3927431A1
(en)
|
2019-02-21 |
2021-12-29 |
Marengo Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
JP7737306B2
(ja)
|
2019-02-21 |
2025-09-10 |
マレンゴ・セラピューティクス，インコーポレーテッド |
Ｔ細胞に結合する多機能性分子および自己免疫障害を処置するためのその使用
|
|
US11613576B2
(en)
|
2019-04-09 |
2023-03-28 |
Sanofi |
Trispecific binding proteins, methods, and uses thereof
|
|
AU2020275002A1
(en)
|
2019-05-14 |
2021-12-23 |
Harpoon Therapeutics, Inc. |
EpCAM binding proteins and methods of use
|
|
MX2021014644A
(es)
|
2019-06-13 |
2022-04-06 |
Amgen Inc |
Control de perfusion basado en biomasa automatizado en la fabricacion de productos biologicos.
|
|
US20220306741A1
(en)
|
2019-09-10 |
2022-09-29 |
Amgen Inc. |
Purification Method for Bispecific antigen-binding Polypeptides with Enhanced Protein L Capture Dynamic Binding Capacity
|
|
WO2021091906A1
(en)
|
2019-11-04 |
2021-05-14 |
Amgen Inc. |
Methods for treating leukemia
|
|
LT3819007T
(lt)
|
2019-11-11 |
2024-10-10 |
Amgen Research (Munich) Gmbh |
Dozavimo režimas, skirtas anti-bcma agentams
|
|
US20220396599A1
(en)
|
2019-11-13 |
2022-12-15 |
Amgen Inc. |
Method for Reduced Aggregate Formation in Downstream Processing of Bispecific Antigen-Binding Molecules
|
|
WO2021119505A1
(en)
|
2019-12-13 |
2021-06-17 |
Genentech, Inc. |
Anti-ly6g6d antibodies and methods of use
|
|
IL293640A
(en)
|
2019-12-20 |
2022-08-01 |
Amgen Inc |
CD40 antagonistic mesothelin-targeted multispecific antibody constructs for the treatment of solid tumors
|
|
AU2020416273A1
(en)
|
2020-01-03 |
2022-07-28 |
Marengo Therapeutics, Inc. |
Anti-TCR antibody molecules and uses thereof
|
|
EP4084821A4
(en)
|
2020-01-03 |
2024-04-24 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to cd33 and uses thereof
|
|
US20230093169A1
(en)
|
2020-01-22 |
2023-03-23 |
Amgen Research (Munch) Gmbh |
Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
|
|
WO2021158469A1
(en)
|
2020-02-03 |
2021-08-12 |
Amgen Inc. |
Multivariate bracketing approach for sterile filter validation
|
|
CN115768463A
(zh)
|
2020-02-21 |
2023-03-07 |
哈普恩治疗公司 |
Flt3结合蛋白及使用方法
|
|
TW202200615A
(zh)
|
2020-03-12 |
2022-01-01 |
美商安進公司 |
用於治療和預防患者的crs之方法
|
|
WO2021188851A1
(en)
|
2020-03-19 |
2021-09-23 |
Amgen Inc. |
Antibodies against mucin 17 and uses thereof
|
|
CN115843312A
(zh)
|
2020-04-24 |
2023-03-24 |
马伦戈治疗公司 |
结合至t细胞相关癌细胞的多功能性分子及其用途
|
|
CA3183756A1
(en)
|
2020-05-19 |
2021-11-25 |
Amgen Inc. |
Mageb2 binding constructs
|
|
US20240209085A1
(en)
|
2020-05-29 |
2024-06-27 |
Amgen Inc. |
Adverse effects-mitigating administration of a bispecific construct binding to cd33 and cd3
|
|
TW202216777A
(zh)
|
2020-07-10 |
2022-05-01 |
美商生質分子控股有限責任公司 |
四面體抗體
|
|
US20230265176A1
(en)
*
|
2020-08-14 |
2023-08-24 |
Chugai Seiyaku Kabushiki Kaisha |
One-armed antigen-binding molecules and uses thereof
|
|
GB2616128A
(en)
|
2020-08-26 |
2023-08-30 |
Marengo Therapeutics Inc |
Antibody molecules that bind to NKp30 and uses thereof
|
|
AU2021331075A1
(en)
|
2020-08-26 |
2023-04-06 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
GB2616354A
(en)
|
2020-08-26 |
2023-09-06 |
Marengo Therapeutics Inc |
Methods of detecting TRBC1 or TRBC2
|
|
WO2022060878A1
(en)
|
2020-09-16 |
2022-03-24 |
Amgen Inc. |
Methods for treating prostate cancer
|
|
MX2023003041A
(es)
|
2020-09-16 |
2023-05-09 |
Amgen Inc |
Métodos para administrar dosis terapéuticas de moléculas de acoplamiento a células t biespecíficas para el tratamiento de cáncer.
|
|
AU2021374594B2
(en)
|
2020-11-04 |
2026-03-05 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
|
|
JP7716473B2
(ja)
|
2020-11-04 |
2025-07-31 |
ジェネンテック， インコーポレイテッド |
抗ｃｄ２０／抗ｃｄ３二重特異性抗体の皮下投薬
|
|
TWI874719B
(zh)
|
2020-11-04 |
2025-03-01 |
美商建南德克公司 |
用抗cd20/抗cd3雙特異性抗體進行治療之給藥
|
|
TW202225188A
(zh)
|
2020-11-06 |
2022-07-01 |
德商安美基研究（慕尼黑）公司 |
與ｃｄ３結合的多肽構建體
|
|
WO2022096704A1
(en)
|
2020-11-06 |
2022-05-12 |
Amgen Inc. |
Antigen binding domain with reduced clipping rate
|
|
UY39507A
(es)
|
2020-11-06 |
2022-03-31 |
Amgen Res Munich Gmbh |
Construcciones polipeptídicas que se unen selectivamente a cldn6 y cd3
|
|
CR20230229A
(es)
|
2020-11-06 |
2023-09-05 |
Amgen Res Munich Gmbh |
Moléculas de unión a antígeno biespecíficas con múltiples dianas de selectividad aumentada
|
|
EP4243936A1
(en)
|
2020-11-10 |
2023-09-20 |
Amgen Inc. |
Methods for administering a bcma x cd3 binding molecule
|
|
TW202233684A
(zh)
*
|
2020-11-18 |
2022-09-01 |
美商泰尼歐生物公司 |
結合於葉酸受體α之重鏈抗體
|
|
WO2022115865A2
(en)
|
2020-11-25 |
2022-06-02 |
Xilio Development, Inc. |
Tumor-specific cleavable linkers
|
|
AR124414A1
(es)
|
2020-12-18 |
2023-03-22 |
Century Therapeutics Inc |
Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
|
|
HUP2100038A1
(hu)
*
|
2021-02-03 |
2022-08-28 |
Richter Gedeon Nyrt |
Mutáltatott rekombináns ACE2-Fc fúziós fehérjék COVID-19 fertõzések kezelésére
|
|
WO2022191971A1
(en)
|
2021-03-10 |
2022-09-15 |
Amgen Inc. |
Parallel chromatography systems and methods
|
|
JP2024509877A
(ja)
|
2021-03-10 |
2024-03-05 |
アムジエン・インコーポレーテツド |
組換えタンパク質の精製方法
|
|
US20250282887A1
(en)
|
2021-04-02 |
2025-09-11 |
Amgen Inc. |
Mageb2 binding constructs
|
|
WO2022216993A2
(en)
|
2021-04-08 |
2022-10-13 |
Marengo Therapeutics, Inc. |
Multifuntional molecules binding to tcr and uses thereof
|
|
CA3213632A1
(en)
|
2021-04-30 |
2022-11-03 |
F. Hoffmann-La Roche Ag |
Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
|
|
JP2024518369A
(ja)
|
2021-05-06 |
2024-05-01 |
アムジェン リサーチ （ミュニック） ゲゼルシャフト ミット ベシュレンクテル ハフツング |
増殖性疾患で使用されるｃｄ２０及びｃｄ２２標的化抗原結合分子
|
|
EP4337330A1
(en)
|
2021-05-14 |
2024-03-20 |
Genentech, Inc. |
Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
|
|
JP2024523033A
(ja)
|
2021-06-17 |
2024-06-25 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
新規の三重特異的結合分子
|
|
CN113337514B
(zh)
*
|
2021-08-05 |
2021-10-29 |
卡瑞济(北京)生命科技有限公司 |
Tcr表达构建体以及其制备方法和用途
|
|
KR20240115809A
(ko)
*
|
2021-10-15 |
2024-07-26 |
싸이톰스 테라퓨틱스, 인크. |
활성화 가능한 폴리펩타이드 복합체
|
|
JP2025500732A
(ja)
|
2021-10-27 |
2025-01-15 |
アムジエン・インコーポレーテツド |
分光法を使用して薬剤を監視するための深層学習ベースの予測
|
|
US20260070986A1
(en)
|
2021-11-03 |
2026-03-12 |
Affimed Gmbh |
Bispecific cd16a binders
|
|
IL312515A
(en)
|
2021-11-03 |
2024-07-01 |
Affimed Gmbh |
Bispecific cd16a binders
|
|
US20250084169A1
(en)
|
2022-01-12 |
2025-03-13 |
Biomolecular Holdings Llc |
Nk/monocyte engagers
|
|
JP2025508882A
(ja)
|
2022-02-28 |
2025-04-10 |
エクシリオ デベロップメント， インコーポレイテッド |
標的化サイトカインおよびその使用方法
|
|
WO2023164286A1
(en)
|
2022-02-28 |
2023-08-31 |
Xilio Development, Inc. |
Engineered cd122 compositions and methods thereof
|
|
EP4522651A1
(en)
|
2022-05-12 |
2025-03-19 |
Amgen Research (Munich) GmbH |
Multichain multitargeting bispecific antigen-binding molecules of increased selectivity
|
|
WO2024015960A1
(en)
|
2022-07-15 |
2024-01-18 |
Xilio Development, Inc. |
Engineered cleavable fc domain as carriers and methods of use thereof
|
|
TW202421650A
(zh)
|
2022-09-14 |
2024-06-01 |
美商安進公司 |
雙特異性分子穩定組成物
|
|
EP4598958A1
(en)
|
2022-10-05 |
2025-08-13 |
Amgen Inc. |
Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof
|
|
KR20250157375A
(ko)
|
2023-03-08 |
2025-11-04 |
암젠 인크 |
이중특이적 분자에 대한 제어된 빙핵 형성 동결건조 공정
|
|
UY40797A
(es)
|
2023-06-14 |
2024-12-31 |
Amgen Inc |
Moléculas captadoras de enmascaramiento de células t
|
|
KR20260049657A
(ko)
|
2023-08-22 |
2026-04-14 |
암젠 인크 |
의약품의 효율적인 포장 방법 및 어셈블리
|
|
WO2025049948A1
(en)
|
2023-08-30 |
2025-03-06 |
Xilio Development, Inc. |
Masked il-2 cytokines and methods of use thereof
|
|
AU2024330564A1
(en)
|
2023-08-30 |
2026-04-02 |
Xilio Development, Inc. |
Vhh masked cytokines and methods of use thereof
|
|
WO2025101672A1
(en)
|
2023-11-06 |
2025-05-15 |
City Of Hope |
Methods comprising oncolytic viruses expressing cd19t and bispecific t cell engagers
|
|
WO2025257588A1
(en)
|
2024-06-10 |
2025-12-18 |
Affimed Gmbh |
Cd16a/tumor antigen polyspecific binder for use in the treatment of immune checkpoint inhibitor resistance
|
|
WO2025259515A2
(en)
|
2024-06-11 |
2025-12-18 |
Amgen Inc. |
Combination treatment
|
|
WO2026011013A1
(en)
|
2024-07-02 |
2026-01-08 |
Epibiologics, Inc. |
Binding agents and uses thereof
|
|
WO2026037841A1
(en)
|
2024-08-12 |
2026-02-19 |
ONA Therapeutics S.L. |
Anti-fgfr4 molecules and uses thereof
|
|
WO2026050572A2
(en)
|
2024-08-29 |
2026-03-05 |
Marengo Therapeutics, Inc. |
Multifunctional molecules binding to tcr and uses thereof
|
|
WO2026072671A1
(en)
|
2024-09-24 |
2026-04-02 |
City Of Hope |
Methods comprising oncolytic viruses expressing bcmat and bcma-targeted therapies
|